可供推廣之研發成果資料表 
■ 可申請專利  □ 可技術移轉                                      日期：98 年 5 月 31 日 
國科會補助計畫 
計畫名稱：具有水難溶藥物包覆能力的超音波敏感釋控材料開發及
其奈米結構設計 II 
計畫主持人：劉澤英         
計畫編號： NSC 97－2221－E－010－012－MY2        
學門領域：醫工學門生醫材料 
技術/創作名稱 一種超音波敏感釋控藥物載體 
發明人/創作人  劉澤英 
中文： 
目前習知的超音波釋控材料主要是以 Pluronic P-105 
(PEO-PPO-PEO triblock copolymer)所形成的 drug-loaded micelle 為
主，另有一部份是將藥物以不同方式攜載於商業化的 ultrasound 
contrast agent 上  (材料多為 phospolipid 或 anionically-charged 
surfactant)，部份產品也已商業化用於抗血栓藥物、抗癌藥物與基
因傳遞上，其主要原理是以 ligand-coated microbubble 中氣體對超
音波而言是不透明的特性來進行影像診斷，再透過空穴效應
(cavitation effect)來促進材料釋出藥物，本計劃所採用之材料與上述
文獻有所區別；另外，本技術所運用的機制也與上述習知技術不同。
技術說明 
英文： 
A novel ultrasonically-sensitive drug carrier was developed by our 
group to encapsulate the poorly water-soluble agents, which was 
different from the traditional technologies such as Pluronic P-105, 
anionically-charged surfactant and phospolipid.    
可利用之產業 
及 
可開發之產品 
超音波影像對比劑 
智慧型藥物載體 
技術特點 
可降低一般超音波釋控載體的背景滲漏 
推廣及運用的價值 
 
※ 1.每項研發成果請填寫一式二份，一份隨成果報告送繳本會，一份送 貴單位研
發成果推廣單位（如技術移轉中心）。 
※ 2.本項研發成果若尚未申請專利，請勿揭露可申請專利之主要內容。 
※ 3.本表若不敷使用，請自行影印使用。 
附件二 
 1
(1) 研究背景與動機 
為達成精準給藥的目地，有相當多的「環境應答(environment response)材料」被用來製成「智慧
型藥物載體(smart drug carrier)」，其可感測外在環境諸如:溫度、pH值與離子等多種刺激因子的變化而
使材料結構改變，並藉此來發揮觸發(trigger)載體釋放藥物的功能，相關研究已被廣泛地報導與應用
[1-3]。近年來，近紅外線(near infrared)、電場、磁場與超音波(ultrasound)等非侵入式的能量形式亦被
用來作為「體外觸發」藥物載體釋放的外部刺激因子(stimuli) [4-7]，也就是說，這些能量可以在體外
遙控(remote control)藥物載體的釋放行為；其中，對電磁場敏感之智慧型載體需透過電磁場來觸發釋
控行為，然而此方式可能對於一般醫療儀器有相當大之干擾，尤其對某些體內已有金屬或電子元件植
入物的病人而言，不易精準聚焦的電磁場可能使此法存在健康風險；另外，近紅外線雖易聚焦但其觸
發啟動方式常因紅外線對組織的穿透深度有限而有使用上的限制 [4]；相較前二者，已在臨床醫學上
使用超過20年的超音波，除了較無前述之不確定因素外，尚兼具：透過現有醫療超音波設備即可進行
能量聚焦、精準定向傳播與較佳的軟組織穿透深度等優點，所以，超音波除了典型的醫學診斷影像用
途外，其實已經被廣泛應用在經皮給藥的臨床醫學治療用途中 [8]；另外，超音波熱療法也已被應用
於癌症治療與物理治療 [9, 10]，最重要的是醫用超音波設備已高度商業化並具備高度的安全性，使
得藉由超音波於體外觸發載體釋藥的「超音波感音觸發藥物載體」極有機會被實際運用在臨床醫學的
用途上，所以如何利用超音波感音觸發藥物載體結合目前的超音波的臨床應用是一個相當值得發展的
研究領域。 
大部分的智慧型藥物載體與一般高分子藥物載體均有類似的共同問題點:「背景滲漏」 (background 
leakage；藥物在體外運送儲存過程中或在體內循環過程尚未達到特定位置被觸發前就從載體洩漏出來) 
[11]，因此，如何克服背景滲漏便成為智慧型藥物載體的重要挑戰。另外，超音波感音載體尚有一個
問題，目前在文獻中對於感音載體的超音波敏感性相關研究多針對類似microbubble、liposome 或是
micelle之類的材料結構，這些結構需透過低頻(20 kHz)之超音波才能達到較高的觸發效率，因為超音
波所產生的壓力震幅可透過MI (mechanical index)值來描述，MI值與超音波頻率存在二分之一次方成反
比的關係，與功率密度二分之一次方呈正比的關係 [12]，所以在高頻率低功率時，對於一般micelle或
liposome載體結構而言，這些載體對於高頻超音波的響應(response)並不明顯[12]，然而醫療診斷用之
超音波頻率多為中高頻(1-10MHz)範圍，所以目前本研究室以1-3 MHz為主要超音波頻率參數，希望可
以透過現有之商業化醫療診斷超音波，來達成超音波觸發釋藥的目的。 
 
(2) 研究目的 
本兩年期計劃，研究目的從材料基礎研究進行至載體結構設計，研究目的可分為下列三項： 
1. 對於「水溶性藥物」而言，本計劃以披覆氫氧基磷灰石的微脂體 (HA-coated liposome)來進行背景
滲漏與高頻(1-3 MHz)超音波觸發釋藥的試驗，研究中深入探討HA殼層厚度與超音波參數對於超音波
釋藥行為的影響。 
2. 對於「水難溶性藥物」而言，本計劃延伸使用本研究室所開發的雙親性幾丁聚糖 carboxymethyl 
hexanoyl chitosan (CHC)來作為可包覆水難溶性藥物的感音載體材料，透過此micelle forming polymer
與親油性改質的FePt 奈米顆粒形成CHC-FePt奈米微球，除可有效吸載水難溶藥物，也可展現高頻率
超音波釋藥的特性。 
3. 在「材料的基礎研究」部分，探討(a) ultrasonically triggered SiO2/CHC hybrid 之帶藥植入物結構與
製程設計，以及SiO2/CHC hybrid 在超音波下的釋放行為；(b) ultrasonically triggered CHC-based之微形
 3
體管柱分離法去除微脂體中未包覆到的藥物溶液。首先，預先配製上述 2.5 % 含有二甲酚橙的微脂體
溶液，並且在微脂體溶液中加入醋酸鈣粉末，調配此溶液濃度為 2.5×10-2 M。另一方面，調配溶液濃
度為 1.5×10-2 M 的磷酸溶液，再以濃度為 5.0×10-2 M 的氫氧化鈉溶液滴定磷酸溶液至 pH 值為 11。
之後，將滴定完成的磷酸溶液以緩慢的速度滴入微脂體/醋酸鈣混和溶液中在室溫下均勻攪拌，此反應
系統的 pH 值為 8，總反應時間為 2 至 8 小時。將以低轉速離心後取上清液，再將上清液以高速離
心，收取沉澱物後分散於水中即可。最後以膠體管柱分離法去除藥物載體中未包覆到的藥物溶液，再
分散於二次水溶液中。接著，將已攜載藥物的釋藥載體裝載於供藥槽 (donor cell)中，再將此供藥槽以
透析膜包覆隔絕 (透析膜隔離方式主要目的為減低藥物載體對藥物吸收值的干擾)並且與受藥槽 
(receptor cell)聯結；最後，再將此藥物釋放裝置放置在搖晃烘箱中，設定烘箱溫度為 37 ℃且搖晃速率
為 100 rpm，藉由藥物從載體中自然擴散出來的方式，在 UV-visible 光譜儀下量測受藥槽內藥物的吸
收值並轉換成藥物濃度 (二甲酚橙特徵吸收峰量測值為 431 nm)。藥物背景滲漏數據圖是由公式: 
(Mt/M)-t 所繪製而成，這裡的 Mt 表示累加各天量測的藥物濃度後所得到的濃度值，另外，以超音波
物理治療儀觸發釋藥載體後量測得到的藥物濃度 (結束持續自然釋放)，再累加之前自然釋放的所有濃
度值後所得到的濃度值則以 M 表示之。 
將已攜載藥物的釋藥載體利用膠體管柱分離法去除載體中未包覆到的藥物溶液，將收集到的藥物
載體均勻分散於二次水溶液中，再立即分裝成兩杯相同體積與濃度的藥物載體溶液；其中一杯溶液裝
載於具有內外雙壁的玻璃管中，此玻璃管連接循環回流水槽控制溫度在 37 ℃，之後，再將超音波物
理治療機的探頭放在上述裝置中觸發藥物載體。實驗組在前 20分鐘不開啟超音波進行藥物的自然釋
放，接著，將超音波開啟 (frequency: 1 and 3 MHz; power density: 0.2, 0.4 and 1.0 W/cm2)持續刺激 20
分鐘，在固定的時間間隔內測試超音波觸發藥物載體釋放行為，同一時間，另一杯溶液則是在釋放期
間不開啟超音波能量以進行藥物自然釋放並作為實驗的對照組 (negative control group)。在固定的時間
間隔內中取出的待測溶液，經低轉速離心後去除載體或碎片對藥物吸收值的干擾，再以 UV-visible光
譜儀下量測藥物的吸收值並轉換成藥物濃度 (二甲酚橙特徵吸收峰量測值為 431 nm)。藥物釋放數據
圖是由公式: ((Met - Mct)/(Me.max - Mc))-t所記錄繪製而成，這裡的 Met表示在實驗組中各時間點所量測的
藥物濃度值，Mct表示在實驗的對照組中各時間點所量測的藥物濃度值；另外，在實驗組中以超音波物
理治療儀觸發釋藥載體後量測得到的最大釋藥濃度值則以 Me.max表示之，而 Mc表示最大釋藥濃度的
時間點在實驗的對照組中所量測得到的濃度值。 
 
PART 2.  
先秤取 Pt(acac)2 49.2mg，Fe(OEt)3 48mg，octyl ether 10 ml 置入 50ml 三頸圓底瓶內。把磁攪拌子
放入三頸圓底瓶內，架設實驗裝置如圖 3.2。將實驗裝置都架設完畢後，通入 Ar 至圓底瓶內，做氣
體置換 30 分鐘以確定將氧氣排出。30 分鐘過後，開啟冷卻水使迴流裝置將溫度控制在低溫，先升溫
至 100℃，持溫 100℃約 10 分鐘，檢查所有溶質是否完全溶解。確定溶質完全溶解後，先後注入油酸
(0.08ml，0.6mmol)和油胺（0.08ml，0.6mmol）。分別加入油酸和油胺後，再升溫至沸騰(約 290℃)，讓
溶劑迴流（reflux）。待溫度上升至溶液迴流後，開始計時反應一小時，迴流期間可觀察到溶液變成黑
色，即表示有產物生成。反應時間結束後，移除熱源讓溶液冷卻至室溫。產物冷卻至室溫後，離心三
次，即可得到 FePt。 
取 2g 產物(NOCC)於 150 ml 反應瓶，內置一磁石，添加 50 ml 純水，攪拌一天至完全溶解後，再
加入 50 ml 甲醇使其混合均勻一天。均勻混和後，再加入 hexanoic anhydride(己酸酐) 1.4 ml 反應八小
時。再反應八小時後，會得黃色透明黏稠狀的產物，將產物透析袋收集，先放置工業級酒精(95％)透
析一天，再以純乙醇透析兩次（每次皆為一天），共透析三天。透析三天後，將產物置於 65℃烘箱乾
 5
結構不緻密，其粒徑大小約為 250 nm；並由圖 1 (b) 中可觀察到 HA-coated liposome-8 殼層較厚實完
整且結構緻密，隨著反應時間的增長，可觀察到外層披覆氫氧基磷灰石的厚度也隨之增加，其粒徑大
小約為 300 nm。透過 TEM 的觀察粒徑變化的結果與 DLS 粒徑量測的結果(表 3)大致相符，同樣可觀
察到，隨著反應時間的增長，HA-coated liposome 之粒徑也由 262 nm 增加到 347 nm。  
為了證實 HA-coated liposome 表層殼層確實為氫氧基磷灰石結構，我們進行了 XRD 的量測，如
圖 2 所示，HA-coated liposome 之 X 光繞射圖譜 (XRD)在圖譜上可明顯的觀察到在 25.94°與 31.78° 
兩處均有繞射峰存在，根據 ICDD No. 46-0905 資料庫比對的結果，可知此二繞射峰分別對應氫氧基
磷灰石之 (002)與 (211)晶面，證實 liposome 的表面確實有沉積氫氧基磷灰石的結構存在，另外，由
繞射峰之半高寬可得知披覆在 liposome 表面的氫氧基磷灰石結晶性不佳。 
本研究以長時間的自然釋放實驗來測試 HA-coated liposome 防止藥物背景滲漏之能力，由圖 3 可
觀察到 liposome 第一天釋放出約 9 %藥物，在第七天累計釋放出的藥物約達包覆總量的 45 %；然
而，HA-liposome-8 在第一天所滲漏出的藥物量極低，且在第七天所累積釋放出的藥量約為 liposome
的 1/3，由此可知，披覆氫氧基磷灰石殼層確實可以有效阻止藥物載體的背景滲漏。此外，如圖 3 結
果所示: HA-liposome-2 結構在 1~3 天累計的藥物釋放量較 HA-liposome-8 結構多出約一倍，主要的原
因可能是 HA-liposome-2 表層披覆之無機殼層較薄且結構不緻密，因此以長時間 (1~7 天)的測試看來
雖有防止藥物背景滲漏之能力，但相較於殼層較為完整緻密的 HA-liposome-8 結構，HA-liposome-2
抵抗藥物背景滲漏能力較弱。  
本研究為了探究 HA-coated liposome對超音波的響應，進行了超音波觸發響應實驗，實驗中將不
同殼層厚度之 HA-coated liposome分別置放於超音波藥物釋放槽中，先進行 20分鐘未施加超音波音場
的釋放實驗，接著進行 20分鐘有施加超音波音場的釋放實驗 (設定超音波頻率為 3 MHz；能量密度
為 1.0 W/cm2)，過程中紀錄藥物的釋放量，而藥物釋放數據圖則以 Rui 值 (Rui = (Met - Mct)/(Me.max - Mc))
與時間所記錄繪製而成，Rui 值表示藥物載體在超音波音場的觸發下所導引出的藥物釋放量，透過上
式，可除去吸附的影響干擾，能夠較準確地反映出ultrasound-induced release。實驗結果如圖4所示: 
HA-coated liposome在超音波音場的導入之後，其藥物釋放量有很明顯的上升趨勢，Rui 值在超音波音
場刺激 5分鐘後釋放量可達到約 50 %，此後，則以較緩的趨勢逐漸達到飽合；除此之外，也由圖4觀
察到披覆無機殼層的厚薄對高頻率超音波的觸發作用的影響不大，實驗中製備出不同殼層厚度的藥物
載體結構對於高頻率超音波音場的振動刺激皆有相當的敏感性，此現象可歸因於：不同厚度的HA殼
層均具有硬脆的本質，其性質均與liposome有相當差異，因此均能在超音波觸發後，迅速地釋放藥物
而無展現顯著差異。此現象可由圖5 (a)震破前與圖5(b) 經超音波震破後在結構上的比較，來證實藥物
載體在超音波音場的刺激下確實能將 HA-coated liposome結構破壞且無再包覆現象，其原因可能是因
為磷脂質分子已與相對堅硬易碎的氫氧基磷灰石殼層結合，一旦經超音波震破此殼層之後，磷脂質分
子無法進行再組裝，因而無再包覆現象。 
在完成無機殼層的厚度對載體的高頻超音波敏感性的討論之後，接下來，本研究也持續探究超音
波頻率對觸發釋藥行為的影響，因 HA-liposome-8 抵抗藥物背景滲漏的能力較佳，因此在實驗中以 
HA-liposome-8 作為待測之藥物載體，探討在不同的超音波頻率的刺激之下 (超音波頻率為 3 MHz 與 
1 MHz；能量密度為 1.0 W/cm2)對於藥物釋放行為是否有所影響。藥物釋放數據圖則以 Rui 值 (Rui = 
(Met - Mct)/(Me.max - Mc))與不同時間所記錄繪製而成。實驗結果如圖 6 所示:在施加 3 MHz 與 1 MHz 之
高頻率超音波音場後，兩者所顯示出的 Rui 值快速上升且藥物釋放趨勢幾近相同，由此現象也能夠證
明在超音波頻率為 3 MHz 與 1 MHz 刺激之下確實可以破壞 HA-coated liposome 結構，使其藥物釋放
量在短時間內能迅速增加，然而，以上兩種超音波頻率對於觸發釋藥行為的行為也並無顯著之影響，
相信也是歸因於硬脆的 HA 殼層對於超音波負壓震幅非常敏感，所以導致不同頻率並無法使觸發行為
 7
示。若改將 CHC 溶液(100 mg CHC/ 10 ml D.I. water)以二次水稀釋 8 倍後，加入 FePt 懸浮溶液 0.1 ml，
進行自組裝後便可以合成 CHC-FePt 的奈米微球，由 TEM 的分析可以看到，合成出來的 CHC-FePt 大
小約在 50~60 nm，且為均勻分散的奈米載體，如圖 11 所示。除了藥物載體的大小符合所需，而且分
散良好之外，經過自組裝之後，幾乎沒有 free 的 FePt 散佈在奈米微球之外，也就是說，絕大部分的
FePt 懸浮溶液均已經和 CHC 自組裝成奈米微球；另外，由圖 12 中可以很明顯的看出，在自組裝過
後，有機溶劑是均勻的分散於水相之中，並沒有明顯的分層。 
合成出 CHC-FePt 奈米微球後，進一步進行材料的分析，我們利用 XRD 來鑑定微球中的無機奈米
顆粒是否為 FePt。如圖 13 所示，藍線的部分是為 FePt，分別在 39.7 度與 46.5 度可以明顯觀察到有繞
射峰的存在，根據國際粉末繞射委員會（JCPDS）所建立的粉末繞射資料可判別此二繞射峰分別為 FePt 
( 1 1 1 )、( 2 0 0 )平面的特徵峰。而紅線的部分是為 CHC-FePt，可觀察到在 39.8 度、46.9 度也有特徵
峰，因此便能確定奈米微球中的無機奈米顆粒為 FePt ，至於繞射峰有寬化的跡象，乃是因為顆粒非
常小所致。 
我們使用 FTIR 來分析奈米微球中是否有 CHC 的存在。辨別 CHC 的三個主要官能基分別為羧酸
(-COOH)、amide I 以及 amide II。如圖 14 所示，在 CHC 的譜圖上可觀察到羧酸(-COOH)的吸收峰約
在 1740 cm-1，而 amide I 以及 amide II 分別約在 1550 cm-1 以及 1640 cm-1；除了這三個主要的官能基
之外，在 1080 cm-1 會有 C-O stretching 的吸收峰；在 1149 cm-1 會有 C-O-C asymmetry 的吸收峰；在 1320 
cm-1 有 C-NH 的吸收峰；以及在 2840~2950 cm-1 有明顯的-CH2，-CH3 stretching 吸收峰。至於 CHC-FePt
的部分，CHC 的三個主要吸收峰只有明顯的觀察到兩個，分別為 amide I 1550 cm-1 的吸收峰以及 amide 
II 1640 cm-1 的吸收峰，羧酸 1740 cm-1 相對 amide I 及 amide II 就小很多。在 CHC-FePt 中沒有明顯觀
察到羧酸 1740 cm-1 的吸收峰，可能是因為濃度太低，羧基以 monomer 存在所致，導致屬於 dimer 的
特徵峰消失，然而，amide I 以及 amide II 的存在應已足夠證明 CHC 是為奈米微球的成分之一。為進
一步證明這樣的觀點，必須確認 CHC 在自組裝過程中所扮演的角色(合成出來的奈米微球有可能只是
FePt 與有機溶劑在水溶液之中自己聚成球形所形成的油相懸浮溶液)，我們設計一組對造組，此對造組
為相同容量的二次水加上相同容量的 FePt 懸浮溶液，經過均質機自組裝後，如圖 15 所示，由 TEM 的
形貌觀察可知：沒有 CHC 的參與，FePt 便以不規則形狀散佈在二次水中，沒有辦法穩定自組裝成 50 nm
大小的奈米微球，所以結合 FTIR 的數據可以說明 CHC 除了是奈米微球的成分之一，亦發揮了穩定奈
米微球的功能。 
在成功合成出 CHC-FePt 奈米微球後，初步由 TEM 得知在超音波觸發後可以成功地將奈米微球擊
散，因此我們便進一步的將水難溶性藥物 ibuprofen (IBU)包覆於 CHC-FePt 之中，希望藉由超音波的
刺激將水難溶性藥物 IBU 從微球之中釋放出來，從文獻中可知，IBU 的加入會使某些高分子的孔洞變
大或是造成型態改變[25, 26]；然而，在本研究中，如圖 16 所示，由 TEM 圖可以證明加入 IBU 後再
經過自組裝並不會破壞 CHC-FePt 奈米微球的結構，CHC-FePt-IBU 仍然是呈現 40~60 nm 的大小；另
外，在藥物包覆效率部分，我們將自組裝後的 CHC-FePt-IBU 用強力磁鐵吸一天，經過兩次的沖洗過
後，計算 CHC-FePt 可包覆的藥量，經過計算後得知包覆率可達到 90.07％，可以說明 IBU 有效率地
被包覆在 CHC-FePt 載體之中。 
超音波 MI 值的大小和頻率成 1/2 次方的反比，頻率越小則 MI 值越大，因此，藉由超音波來釋放
藥物，其釋放行為與超音波本身的頻率及功率應有相當的關聯性，因此，我們使用不同頻率以及不同
功率來觀察疏水性藥物 IBU 在 CHC-FePt 奈米微球中的釋放情形。首先，我們先讓 CHC-FePt-IBU 自
然釋放 50 分鐘後，再將超音波開啟，開啟觸發兩分鐘後，再讓 CHC-FePt-IBU 釋放 50 分鐘。由圖 17
中可以明顯得知，讓 CHC-FePt-IBU 在沒有經過超音波的觸發的情況下自然釋放 50 分鐘，期間幾乎沒
有藥物的釋放；然而，在自然釋放 50 分鐘後使用超音波觸發 CHC-FePt-IBU，由圖中可以很明顯的看
 9
可撓性也會降低，同時也伴隨體積的縮小，這樣的現象，可以透過下述反應方程式來說明： 
Si-OH + HOCH2CH(OH)CH2OH Æ  
Si-OCH2CH(OH)CH2OH + H2O                  (1) 
Si-OCH2CH(OH)CH2OH + Si-OH Æ  
Si-O-Si + HOCH2CH(OH)CH2OH (remains in pore)  (2) 
Si-OCH2CH(OH)CH2OH + Si-OCH2CH(OH)CH2OH Æ 
-Si-OCH2CHOHCH2O-Si- (3D structure) + H2O     (3) 
由上述方程式可知，DMSO與glycerol 的加入，會使部分glycerol 分子以共價鍵的型式稼接在O-Si-O 的
鍵結中，形成交聯度較低的網狀結構，分子線性的程度較高，所以產生了可撓曲的特性；另一部分的
glycerol 與DMSO、ethanol以及H2O的混合溶液則以自由溶劑的形式存在於網狀結構內的孔隙中，當試
片置於水中浸泡，外界的水會將這些自由溶劑脫出孔隙結構之外，同時會使穩定性不佳的 
-Si-OCH2CHOHCH2O-Si- 線性鏈段進行二次縮合，使帶有甘油鏈段的SiO低交聯結構朝向高交聯網狀
的SiO2 配位結構發展，因而伴隨了體積的減少與可撓性的降低；超音波可能可以提供能量使二次縮合
加速，使溶劑脫出的速度與程度都獲得增加 (圖20)，也使結構更接近完整的SiO2 結構(圖21)。圖22
為試片CHC/SiO2/GD分別在剛合成完畢未經DI水浸泡(as received)、在無超音波場下經DI水浸泡
(without sonication)以及在有超音波場下經DI水浸泡(under sonication)所取得的FTIR光譜，其對於超音
波的響應行為類似試片SiO2/GD，也就是說超音波的作用均有助於自由溶劑的脫出。然而，在FTIR光
譜上值得注意的兩個小差異分別是：剛合成完畢未經DI水浸泡的CHC/SiO2/GD 可觀察到3738 cm-1特
徵峰肩(lone silanol SiO-H stretch)，而此特徵峰肩無法在未經DI水浸泡的SiO2/GD 試片上被明顯觀察
到，意謂CHC的添加會減少hydrogen bonded silanol (-SiOH…OHSi-)生成的機會因而造就較多的lone 
silanol (SiO-H)；另一個差異為797 cm-1 特徵峰(O-Si-O symmetric stretch)只能在未經DI水浸泡的
SiO2/GD 試片上被觀察到而未出現在CHC/SiO2/GD (as received)的譜圖中，說明了CHC 分子會阻擾
O-Si-O的鍵結生成。上述兩個在光譜上觀察到的現象可以推測CHC/SiO2/GD交聯度較低且結構較開
放，造成CHC分子在無超音波作用的狀況下就可離開主結構，使進一步的縮合自發進行，也使自由溶
劑的脫出量增加，此推測可由圖20的觀察得到證明：CHC的添加使hybrid接受超音波作用前後的差異
變得較不顯著，換言之，hybrid 的超音波敏感特性可藉由CHC的添加而獲得調控。 
本研究也對SiO2/GD 以及CHC/SiO2/GD hybrid 對於不同性質藥物之包覆效率與超音波觸發釋放
行為進行探討。就monolithic type 試片之藥物包覆效率而言，如圖23所示，在CHC/SiO2/GD hybrid 對
於中性的vitamin B12、水難溶性的氯黴素以及帶正電的亞甲藍都較SiO2/GD hybrid展現了較SiO2/GD高
的包覆效率。對於vitamin B12而言，可能是孔隙率較高所帶來的影響；對於氯黴素而言，包覆效率的
差異應該來自CHC的疏水基對於氯黴素的親和性之貢獻；對於帶正電的亞甲藍而言，可能是帶負電的
CHC分子所產生的影響；對於帶負電的甲基橙而言，帶負電的CHC則會使包覆效率下降。 
圖24至圖27為不同藥物在試片SiO2/GD 以及CHC/SiO2/GD hybrid中之超音波釋藥行為(monolithic 
type 試片)，由此初步結果可知：超音波觸發釋藥行為也與藥物本質(分子量、帶電性以及親疏水性)
有著相當密切的關係。 
本計劃第三部分是透過多種方法來形成具有超音波敏感性質的微載體結構，第一種方式是透過乳
化法將前述 SiO2/GD 以及 CHC/SiO2/GD 作成直徑約 500 nm 的帶藥微球(drug-loaded microsphere)，
由本報告第一部分可知該結構具有在超音波轟擊釋放藥物後有體積大幅縮小的特性，因此有機會被腎
臟(腎臟可排空高度親水小分子量的物質)透過尿液排出體外；然而，此方式經初步實驗，作成微球後
會使藥物包覆效率偏低(低於 50 %)，原因是在乳化的過程中就已經開始產生自由溶劑的脫出，使得水
難溶性藥物也提早離開載體，目前透過不同的界面活性劑與高分子披覆製程持續改善中，主要目的在
隔絕自由溶劑的脫出，使背景滲漏的現象降低以使超音波釋藥的作用更加明顯；另外，預期其可藉由
 11
liposome，其可包覆水溶性藥物且具備低背景滲漏，是較微脂體為佳的感音載體；(4) 成功製備出具創
新結構的CHC-FePt奈米微球，其可包覆水難溶性藥物，亦可透過高頻超音波來觸發。 
c. 技術創新： 
(1) 根據不同藥物特性設計出適合的奈米載體； 
(2) 超低背景滲漏之奈米智慧型載體結構設計； 
(3) 在高頻(1-3 MHz)中低功率密度(小於1 W/cm2)的超音波下，展現較微脂體為優之觸發敏感性。 
d. SCI論文與專利： 
目前本計劃之學術性成果已完成3篇SCI論文之投稿：兩篇分別被Acta biomaterialia (I.F. 3.9) 接受
(一篇已線上刊登，一篇印刷中)，尚有一篇於Journal of controlled release進行審查中，屬於本計劃的成
果應可再發表1-2篇SCI論文(撰寫中)；目前也已經完成一件專利申請(審查中；申請號 099127416，申
請日2010.08.17)。 
e. 應用價值與未來展望： 
本系列研究是從2007開始(2007/08/01-2008/07/31)，該前期計劃完成高分子材料在超音波環境下的
滲透係數基礎研究，接續本兩年期計劃(2008/08/01 - 2010/07/31)，將材料製備成奈米結構後探討其超
音波觸發釋藥的特性；另外，因超音波診斷與醫療設備已非常普及，所以超音波觸發載體極具醫療應
用價值，已進一步的與磁振造影結合並會在短期內開始進行動物體內造影與觸發實驗，目前已取得新
的三年期計劃(2010/08/01 - 2013/07/31)朝此方向持續發展中。 
f. 社會影響 
在實驗設施方面，本研究室透過本系列計劃(三年設備費總額僅約100萬元)搭配其它計劃與學校配
合款建置了許多核心設施(FTIR, DLS, UV 光譜儀，超音波釋藥量測設施等總金額約300萬的設備)供自
己的學生以及本校牙醫系同仁實驗室使用。在人員訓練部分，本計劃已培育出3位碩士班畢業生以及3
位碩士班在學生。 
g.整體評價： 
本計劃之成果尚稱豐碩，經費使用亦達最大效益，且本計劃與其前後期計劃間均能維持相當之連
貫性與創新性。最後，在此感謝國科會所提供的計劃經費支持，使本研究室可從材料基本性質、奈米
結構、造影與釋藥多功能載體乃至生物模式試驗進行一系列的研究，使研究室的學術成果能夠更貼近
生醫應用。 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 13
 
 
   
圖 1. TEM 影像 (a) HA-liposome-2 and (b) HA-liposome-8。 
 
 
 
20 30 40 50 60 70
(3
04
)(1
02
)
(0
04
)
(2
13
)
(2
22
)
(3
10
)
(2
11
)
(00
2)
 
 
In
te
ns
ity
 (a
. u
.)
2 θ (degrees)
 Hydroxyapatite
 HA-coated liposome (HA-liposome-2)
 Liposome
 
圖 2. Liposome、HA-coated liposome 以及 HA 的 X-ray diffraction patterns。 
 
 
 
 
 
 
 15
10 15 20 25 30 35 40
0
20
40
60
80
100
3 MHz
Ultrasound
on
Ultrasound 
off
 
 
U
ltr
as
ou
nd
-in
du
ce
d 
re
le
as
e
R
ui
 (%
)
Time (mins)
 HA-liposome-2
 HA-liposome-8
 Liposome, 3 MHz
 
圖 4. HA 厚度對 Liposome 及 HA-coated liposomes 超音波觸發釋放行為的影響 (ultrasound frequency 
3 MHz; power density 1 W/cm2)。 
 
 
 
  
圖 5. HA-coated liposomes 的 TEM 影像 (a) 轟擊前；(b) 轟擊後。 
 
 
 
 17
0.2 0.4 0.6 0.8 1.0
0
4
8
12
16
Ultrasound
3 MHz
 
 
R
ui
 a
t f
ir
st
 m
in
ut
e 
(%
)
Power density (W/cm2)
 HA-liposome-2
 HA-liposome-8
 Liposome
 
圖 7. 能量密度對 Liposome 及 HA-coated liposomes 超音波觸發釋放敏感性的影響(HA-liposome-8; 
frequency 3 MHz)。 
 
 
 
圖 8. FePt 的 TEM 圖，為化學還原法製備的 FePt。 
 
 19
 
圖 12. CHC-FePt 自組裝後溶液並無分層現象。 
 
20 40 60 80
 
 
A
.U
.
Diffraction Angle, 2 theta (degree)
  
----- CHC-FePt
----- FePt
(2 0 0)
(1 1 1)
 
圖 13. FePt 以及 CHC-FePt 的 XRD 圖。 
 
 21
 
0 20 40 60 80 100
0
20
40
60
80
100
US OFFUS ONUS OFF
 
 
C
um
ul
at
iv
e 
re
le
as
e 
am
ou
nt
 (%
)
TIMES (MIN)
 (1MHz) Ultrasound OFF/ON
 (3MHz) Ultrasound OFF/ON
 
圖 17. CHC-FePt-IBU 在超音波頻率為 1MHz 和 3MHz 的作用下之藥物釋放曲線。 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 23
 
 
 
圖 19. (a) Chitosan/SiO2/GD hybrid；(b) CHC/SiO2/GD hybrid。  
 
 
0 50 100 150 200
60
80
100
 
 
W
ei
gh
t l
os
s (
%
)
Time (min)
Under sonication
 SiO2/GD 
 CHC/SiO2/GD 
Without Sonication
 SiO2/GD 
 CHC/SiO2/GD 
 
圖20. 試片SiO2/GD 與CHC/SiO2/GD 分別在有無超音波作用下浸泡的重量損失。 
4000 3000 2000 1000
 
 
Tr
an
sm
itt
an
ce
 (%
)
Wavenumber (cm-1)
SiO2/GD
 As received
 Without sonication
 Under sonication
 
圖21. 試片SiO2/GD分別在剛合成完畢未經DI水浸泡(as received)、在無超音波場下經DI水浸泡(without 
sonication)以及在有超音波場下經DI水浸泡(under sonication)所取得的FTIR光譜。  
(a) (b) 
 25
0 50 100 150 200 250
20
40
60
80
100
Vitamin B12
 
 
M
t/M
8
Time(min)
SiO2/GD
 Under sonication 
 Without sonication
CHC/SiO2/GD
 Under sonication 
 Without sonication 
 
圖 24. Monolithic 型試片超音波敏感釋藥曲線圖(vitamin B12)。 
 
0 50 100 150 200 250
20
40
60
80
Chloramphenicol
 
 
M
t/M
8
Time(min)
SiO2/GD
 Under sonication 
 Without sonication
CHC/SiO2/GD
 Under sonication 
 Without sonication 
 
圖25. Monolithic 型試片超音波敏感釋藥曲線圖(氯黴素)。 
 
 27
 
 
圖 29. 經超音波轟擊後之 CHC nanocapsule-loaded alginate microsphere 之共軛焦顯微鏡照片(中央白色
箭號指向橙色螢光區域為崩毀之 alginate 微球；圖中綠色亮點為綠螢光染色之 CHC nanocapsule 團聚
物)。 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 29
Avnir, Triggered release of aqueous content from liposome-derived sol-gel nanocapsules. Langmuir 23(24) 
(2007) 12024-12031. 
[19] L. Martin, C.G. Wilson, F. Koosha, L. Tetley, A.I. Gray, S. Senel, I.F. Uchegbu, The release of model 
macromolecules may be controlled by the hydrophobicity of palmitoyl glycol chitosan hydrogels. J. Control. 
Release 80(1-3) (2002) 87-100. 
[20] V.M. Ramos, N.M. Rodriguez, M.F. Diaz, M.S. Rodriguez, A. Heras, E. Agullo, N-methylene 
phosphonic chitosan. Effect of preparation methods on its properties. Carbohydrate Polymers 52(1) (2003) 
39-46. 
[21] Z. Can, Q.N. Ping, H.J. Zhang, S. Jian, Preparation of N-alkyl-O-sulfate chitosan derivatives and 
micellar solubilization of taxol. Carbohydrate Polymers 54(2) (2003) 137-141. 
[22] Y.J. Tong, S.F. Wang, J.W. Xu, B.S. Chua, C.B. He, Synthesis of O,O '-dipalmitoyl chitosan and its 
amphiphilic properties and capability of cholesterol absorption. Carbohydrate Polymers 60(2) (2005) 
229-233. 
[23] S. Saita, S. Maenosono, Chemical ordering of FePt nanoparticles by pulsed laser annealing. Journal of 
Physics-Condensed Matter 16(36) (2004) 6385-6394. 
[24] S. Saita, S. Maenosono, Formation mechanism of FePt nanoparticles synthesized via pyrolysis of 
iron(III) ethoxide and platinum(II) acetylacetonate. Chemistry of Materials 17(26) (2005) 6624-6634. 
[25] Y. Kawashima, T. Iwamoto, T. Niwa, H. Takeuchi, T. Hino, SIZE CONTROL OF IBUPROFEN 
MICROSPHERES WITH AN ACRYLIC POLYMER BY CHANGING THE PH IN AN AQUEOUS 
DISPERSION MEDIUM AND ITS MECHANISM. Chem. Pharm. Bull. (Tokyo). 41(1) (1993) 191-195. 
[26] Y. Kawashima, T. Niwa, H. Takeuchi, T. Hino, Y. Ito, CONTROL OF PROLONGED DRUG RELEASE 
AND COMPRESSION PROPERTIES OF IBUPROFEN MICROSPONGES WITH ACRYLIC POLYMER, 
EUDRAGIT-RS, BY CHANGING THEIR INTRAPARTICLE POROSITY. Chem. Pharm. Bull. (Tokyo). 
40(1) (1992) 196-201. 
 
 
images during which drug carriers might be triggered earlier and/
or at the wrong sites. Hence, it is reasonable to probe images of
ultrasonically triggered drug vehicles with magnetic resonance
(MR) imaging rather than with US (i.e. MR-guided vehicles) [19].
In this paper, a novel MR image-guided drug vehicle capable of
ultrasonically triggered release was developed by incorporating
nanoparticles of superparamagnetic iron oxide (SPIO) into HA-
coated liposomes. It was expected that speciﬁc sites accumulating
a certain amount of vehicles could be probed via MR imaging, and
the subsequent release of the agent could be triggered via US. Hong
et al. also reported that polymeric micelles could demonstrate the
concentration contrast of T2-weighted MR images by encapsulating
differing amounts of superparamagnetic nanoparticles into the
vehicles [20]. However, it remains unclear whether the HA coating
layer and US triggering alters the contrast of MR images. Few stud-
ies have been performed on this issue, which requires further
examination.
The objective of this study is to investigate the ultrasonically
triggered behaviors of HA-coated liposomes in relation to HA thick-
ness and US parameters (i.e. frequency and power density). In
addition, a preliminary investigation on the effects of HA coating
and US triggering on the MR image contrast of HA-coated lipo-
somes encapsulating SPIO was carried out. An understanding of
the ultrasonically active behaviors of HA-coated liposomes could
provide fundamental and valuable information for the design and
fabrication of MR image-guided drug carriers capable of remotely
triggered release.
2. Materials and methods
L-a-Lecithin (minimum 60% TLC), xylenol orange sodium salt,
phosphoric acid (99%), calcium acetate hydrate, sodium hydroxide
and methyl alcohol (anhydrous, 99%) were purchased from Sigma–
Aldrich.
2.1. Preparation of drug-loaded liposome, HA-coated liposome and
HA-coated liposome encapsulating SPIO
L-a-Lecithin was dissolved in 1 ml of methyl alcohol at 54 C.
The methyl alcohol was then evaporated by using a vacuum evap-
orator, and a thin ﬁlm of lipid was coated onto the wall of a 20 ml
round glass ﬂask. The obtained lipid thin ﬁlm was then loaded with
a neutrally charged model drug (xylenol) by rehydrating with
10 ml of a xylenol/DI solution (1000 ppm). The resulting solution
was vortexed and sonicated by probe sonication for 2 min to obtain
drug-loaded liposomes. The excess unloaded drug in the liposome
suspension was removed by gel ﬁltration chromatography.
Drug-loaded liposomes coated with HA layers of varying thick-
nesswere synthesizedby the co-precipitationmethodwithdiffering
reaction times [21]. In brief, the above-mentioned drug-loaded lip-
osomes were ﬁltered using size exclusion chromatography to re-
move unloaded drug. The drug-loaded liposome suspension
collected from the ﬁltration column was then immediately mixed
with calcium acetate solution (2.5  102 M, 10 ml). Subsequently,
a phosphoric acid solution (1.5  102 M, 10 ml) was added drop-
wise to the suspension and the pH value was kept at 11 by a sodium
hydroxide solution (1 M). The thickness of HA was tuned by using a
reaction time ranging from 2 to 8 h. The resulting suspension
containing the drug-loaded vehicles was mildly centrifuged at
4000 rpm and then ﬁltered by a gel column to remove the free HA
and leaked drug for further characterization and release tests. The
names of the specimens are summarized in Table 1. HA-coated
liposomes encapsulating SPIO nanoparticles (6–10 nm),whichwere
prepared using a process similar to HA–liposome-8 sample, were
named HA–liposome–SPIO. The SPIO nanoparticles were
encapsulated in the liposomes prior to the HA coating process. The
encapsulation process was brieﬂy described as follows. The above-
mentioned lipid ﬁlm (0.1 g) was mixed with hexane solution
(10 ml) and Fe3O4 nanoparticle suspension (0.67 vol.%, 1.5 ml) to
form a W/O emulsion. Hexane was then evaporated by using a vac-
uum evaporator, and a lipid–SPIO ﬁlm was obtained. The resulting
ﬁlm was then rehydrated with 10 ml of a xylenol/DI solution
(1000 ppm). The resulting solution was vortexed and sonicated by
probe sonication for 2 min to obtain the liposomes loadedwith drug
and SPIO.
2.2. MR imaging (MRI) characterization
MRI experiments were performed with a 3.0 T clinical scanner
(Siemens). The effective transverse relaxation time (T2) incorpo-
rates the natural transverse relaxation time (T2) and the effect of
magnetic inhomogeneities (T 02) produced by superparamagnetic
particles (i.e. 1/T2 = 1/T2 + 1/T
0
2). The transverse relaxation rate
(R2; R2 = 1/T2) was determined by probing transverse images using
a 2-D spin-echo MR sequence with 30 echoes and an echo time of
22.5 ms. The imaging parameters used were a repetition time of
2000 ms, a ﬁeld of view of 320 mm, a slice thickness of 3 mm, a
192  192 imaging matrix and a ﬂip angle of 180. The effective
transverse relaxation rate (R2; R

2 = 1/T

2) was determined by prob-
ing transverse images using a 2-D gradient-echo MR sequence with
12 echoes and an echo time of 4 ms. The imaging parameters used
were a repetition time of 300 ms, a ﬁeld of view of 320 mm, a slice
thickness of 2 mm, a 192  192 imaging matrix and a ﬂip angle of
30. Finally, the slopes of the curves plotting the R2 and R2 relaxa-
tion rates as a function of vehicle concentration were calculated
and deﬁned as relaxivity values r2 and r2, respectively [22].
2.3. Materials characterization
The crystallographic phase of HA-coated liposomes was identi-
ﬁed by X-ray diffraction (XRD; M18XHF, Mac Science, Tokyo, Ja-
pan), at a scanning rate of 4 (in units of 2hmin1) over a range
of 2h from 20 to 70. Microstructural observations were per-
formed by transmission electron microscopy (TEM) using a Philips
Tecnai 20 operated at 200 keV. The size distributions of drug vehi-
cles were measured via a particle size analyzer (Malvern, ZS90)
using dynamic light scattering (DLS).
2.4. Determination of background leakage
The background leakage of drug-loaded vehicles was measured
using a side-by-side diffusion cell. While unloaded drug was re-
moved via gel chromatography, the suspension containing the
drug-loaded vehicles was immediately added to the donor cell. A
dialysis membrane was ﬁxed between the donor and receptor cells.
Phosphate-buffered saline (PBS) solution was used as the release
medium (pH 7.4 ± 0.02, 37 ± 0.2 C). The drug released in the donor
cell could permeate through the dialysis membrane to the receptor
cell, where the concentration of the permeated drug was measured
using UV–visible spectroscopy (Agilent 8453) at an absorption
peak of 431 nm for each juncture. The vehicles were kept in the do-
nor cell to avoid inaccuracies in determining concentration caused
by optical interference from nanosized vehicles in the receptor cell.
The drug-release proﬁle was recorded by plotting the (Mt/M)  t
curve, where Mt and M, respectively, are the amounts of drug re-
leased at time t and after sonication (20 kHz for 5 min and
1 MHz for 5 min) at the end of the release duration.
2.5. Determination of ultrasonically triggered release behavior
Once the ﬁltered suspension containing the drug-loaded vehi-
cles had been collected from the gel column, it was immediately
2 T.-Y. Liu et al. / Acta Biomaterialia xxx (2010) xxx–xxx
Please cite this article in press as: Liu T-Y et al. Study of a novel ultrasonically triggered drug vehicle with magnetic resonance properties. Acta Biomater
(2010), doi:10.1016/j.actbio.2010.09.018
performed without sonication for the initial 20 min and then with
US triggering at a high frequency (1 and 3 MHz) for the next
20 min. The amount of US-induced release was determined by
deﬁning Rui (i.e. Rui = (Met Mct)/(Me.max Mc)), to eliminate the ef-
fects of drug desorption and natural diffusion from intact vehicles.
The Rui-time plots of HA-coated liposomes were recorded as func-
tions of HA thickness and US frequency. As shown in Fig. 4, under
high-frequency US bombardment, HA-coated liposomes signiﬁ-
cantly demonstrated an US-induced release behavior which was
not observed for liposomes. According to the basic theory of US,
the maximum amplitude of the pressure pulse induced by US could
be illustrated via the mechanical index (MI). It is known that MI is
deﬁned as the peak negative pressure (P, which is proportional to
the square root of the US power density) divided by the square root
of the US frequency. Hence, at high frequency (1–3 MHz), the
amplitude of the pressure pulse is not big enough to destroy the
‘‘ﬂexible” structure of liposome even though the power density
was increased [8,23]. However, the similar amplitude of the pres-
sure pulse might easily destroy the ‘‘semi-brittle” HA-coated lipo-
somes, causing the prominent US-induced release. On the other
hand, as shown in Fig. 4, US-triggered release was not signiﬁcantly
altered by HA thickness, presumably because the brittle nature of
the HA layer was signiﬁcantly altered.
This rapid increase may be evidenced by the TEM photographs
of HA-coated liposomes before (Fig. 5a) and after (Fig. 5b) sonica-
tion (3 MHz). As shown in Fig. 5, the US clearly had an impact in
altering the morphology. The HA shell fragments were observed
and the intact HA-coated liposomes were not observed in Fig. 5b,
implying that the HA-coated liposomes were destroyed after soni-
cation. This accounts for the rapid ﬁrst-stage release (i.e. burst re-
lease) triggered by the high-frequency US. Moreover, re-
encapsulation, a common phenomenon in liposomes, was not ob-
served in any of the HA-coated liposome samples because the
phosphate lipid molecules attached to the HA shell fragments
could not reassemble. On the other hand, Fig. 6 presents the effect
of US frequency on the US-triggered release of HA-coated lipo-
somes. As can be seen, the HA-coated liposomes demonstrated
similar US sensitivities at US frequencies of 3 and 1 MHz. This is
attributable to the fact that the inﬂexible HA coating layer can be
destroyed even when the pressure pulse-induced volume oscilla-
tion is extremely low under high US frequency (3 MHz) [8,23].
As shown in Figs. 4 and 6, Rui was very low during the initial
20 min (without sonication) for all HA-coated liposomes, after
which it drastically increased (i.e. burst release) upon sonication.
Based on these results, we next determined the US sensitivity by
recording the Rui value at the ﬁrst minute under sonication in the
US triggering test performed under a high US frequency (3 MHz).
The Rui values of pristine liposome (without HA coating), HA–lipo-
some-2 and HA–liposome-8 samples obtained at various power
densities are shown in Fig. 7. As can be seen, the Rui values of
HA-coated liposome samples were higher than those of uncoated
liposome samples under the same test conditions (US frequency
and power density). This implies that the release of encapsulated
drug in HA-coated liposomes can be effectively triggered with a
high-frequency US (3 MHz) even at a low power density
(0.2 W cm2). Nevertheless, while the power density was slightly
higher than the threshold value, it is impossible to immediately de-
stroy all vehicles in the release tank after sonication due to the fact
that the decay of US energy is proportional to the distance from US
tip to vehicles. Thus, vehicles could be effectively triggered only in
the limited region (i.e. the effective volume for triggering) near the
US tip. This argument could be supported by the US-triggering re-
lease proﬁles shown in Figs. 4 and 6. As shown, the Rui values
reached around 70% at the ﬁrst 10 min of sonication, after which
they showed a slower ascent during the rest of the sonication per-
iod. In other words, time was needed to destroy all vehicles in the
release tank under continued sonication. If this argument is true, it
is reasonable to believe that the Rui values of HA-coated liposomes
Fig. 2. X-ray diffraction patterns of liposome, HA-coated liposome and HA samples.
Fig. 3. Background leakage behaviors of liposome, HA–liposome-2 and HA–
liposome-8 samples (n = 5).  Denotes signiﬁcant difference (independent two-
sample t-test, P < 0.05) between control (liposome) and HA-coated liposomes.
Fig. 4. Effect of HA thickness on the ultrasonically triggered release behavior of HA-
coated liposomes characterized under ultrasound with a frequency and power
density of 3 MHz and 1 W cm2, respectively.
4 T.-Y. Liu et al. / Acta Biomaterialia xxx (2010) xxx–xxx
Please cite this article in press as: Liu T-Y et al. Study of a novel ultrasonically triggered drug vehicle with magnetic resonance properties. Acta Biomater
(2010), doi:10.1016/j.actbio.2010.09.018
indicating the ability to shorten the T2 relaxation time) of 49.96.
Comparing Fig. 9a and b, the r2 value of HA–liposome–SPIO samples
was signiﬁcantly lower than that of liposome–SPIO samples,
suggesting that HA-coating signiﬁcantly reduces the r2 value. In
contrast, the r2 value was not signiﬁcantly affected by HA-coating,
implying that HA–liposome–SPIO could be probed with the MR T2
signal rather than with the T2 signal.
In the present paper, HA–liposome–SPIO was developed to act
not only as a MR image-guided drug vehicle but also as a MR repor-
ter for monitoring US triggering. An MR reporter which monitors
thermal triggering has been investigated by Salomir et al., who em-
ployed a thermosensitive liposome to encapsulate a paramagnetic
agent and drug that could simultaneously be released via thermal
triggering [24]. The contrast of T1 (spin–lattice relaxation time)
images after thermal triggering is altered because the paramag-
netic agent released from the destroyed vehicles acts as a T1 relax-
ation sink for water protons outside the vehicles. In this study, the
T2 agent (SPIO) was selected as an alternative to probe US-trig-
gered release by creating differences in T2 relaxation instead of
T1 relaxation, owing to the fact that SPIO has long been used to
probe liver tumors with T2 images [25]. The effect of US triggering
on the T2 relaxation of HA–liposome–SPIO is shown in Fig. 9b and
c. The r2 value was not signiﬁcantly altered while HA–liposome–
SPIO was bombarded with US. However, the r2 value was signiﬁ-
cantly reduced after sonication. In other words, the difference
between r2 and r2 (r

2–r2) decreased after sonication. This could
be attributed to the difference in magnetic susceptibility between
clustered and dispersed SPIO, which establishes differing degrees
of magnetic inhomogeneities. These observations on R2 and R

2
agree with the report of Kuhlpeter et al., in which the r2–r2 values
of free SPIO (dispersed SPIO) were higher than cell-bound SPIO
(clustered SPIO) [22]. This suggests that the MR t2 signal of
HA–liposome–SPIO changes after US triggering. It implies that
encapsulating SPIO could confer upon HA–liposomes an MR T2 re-
porter function for monitoring US-triggered release of SPIO-loaded
vehicles.
In this paper, in vitro US-induced release behaviors and in vitro
MR imaging were studied. The in vivo behaviors, including blood-
contacting behaviors, in vivo release behaviors, in vivo MR images
and the side effect of the fragments of the drug vehicle proposed,
need to be further explored and will be shortly be published
separately.
4. Conclusion
In the present study, we successfully fabricated a novel ultra-
sonically triggered drug vehicle by coating liposomes with a thin
layer of HA. The HA layer signiﬁcantly reduced background leakage
and enhanced the response to US triggering at a high frequency (1
and 3 MHz) and low power density (0.2–0.4 W cm2). Further-
more, the novel ultrasonically triggered vehicle encapsulating SPIO
nanoparticles exhibited MR T2 imaging contrast. Introducing the
HA coating layer reduced the natural transverse relaxivity (r2).
Although the effective transverse relaxivity (r2) was not affected
by HA coating, it was signiﬁcantly altered after sonication.
Acknowledgements
The authors gratefully acknowledge the National Science Coun-
cil of the Republic of China for its ﬁnancial support through con-
tract NSC 97-2221-E-010-012-MY2. The authors also thank Prof.
Chu W.C. (National Yang-Ming University, Taipei, ROC) for techni-
cal support.
Appendix A. Figures with essential colour discrimination
Certain ﬁgures in this article, particularly Figures 2, 3, 4, 6, 7, 8
and 9, are difﬁcult to interpret in black and white. The full colour
images can be found in the on-line version, at doi:10.1016/
j.actbio.2010.09.018.
Fig. 9. Transverse relaxation rate (R2) and effective transverse relaxation rate (R

2)
as a function of the concentration of sample vehicles of (a) liposome–SPIO before
sonication, (b) HA–liposome–SPIO before sonication and (c) HA–liposome–SPIO
after sonication. (Samples were mixed with 2% agarose solution and scanned under
a 3.0 T MRI scanner.).
6 T.-Y. Liu et al. / Acta Biomaterialia xxx (2010) xxx–xxx
Please cite this article in press as: Liu T-Y et al. Study of a novel ultrasonically triggered drug vehicle with magnetic resonance properties. Acta Biomater
(2010), doi:10.1016/j.actbio.2010.09.018
Novel pH-sensitive chitosan-based hydrogel for encapsulating poorly
water-soluble drugs
Tse-Ying Liu *, Yi-Ling Lin
Institute of Biomedical Engineering, National Yang-Ming University, 155, Sec. 2, Lih-Nong St., Taipei, Taiwan, ROC
a r t i c l e i n f o
Article history:
Received 22 April 2009
Received in revised form 31 August 2009
Accepted 5 October 2009
Available online 9 October 2009
Keywords:
Chitosan derivatives
pH-sensitive hydrogel
Cell compatibility
Controlled release
a b s t r a c t
Carboxymethyl–hexanoyl chitosan (CHC) is an amphiphilic chitosan derivative with excellent swelling
ability and water solubility under natural conditions. In this work, the inﬂuence of the degree of carboxy-
methyl and hexanoyl substitution on the pH-sensitive swelling behavior, drug release behavior, and
antiadhesion behavior of CHC hydrogels (cross-linked with genipin) were studied. It was found that
the pH sensitivity was more pronounced in CHC than in N,O-carboxymethyl chitosan because the hexa-
noyl group altered the state of water in CHC by inhibiting intermolecular hydrogen bonding. In addition,
greater pH sensitivity was observed in samples bearing longer hydrophobic chains (carboxymethyl–
palmityl chitosan). Interestingly, when used with ibuprofen (a poorly water-soluble therapeutic agent
used here as a model drug), the bursting release of the drug was less prominent in the CHC samples
having a high degree of carboxymethyl substitution. The CHC hydrogel also demonstrated good cell com-
patibility and its antiadhesive ability after grafting was altered by changes in the degree of hexanoyl
substitution.
 2009 Acta Materialia Inc. Published by Elsevier Ltd. All rights reserved.
1. Introduction
In recent years, considerable attention has been focused on
chitosan (CS) hydrogels and their use in tissue engineering scaf-
folds, controlled release and implants [1–3]. This is because of their
glycosaminoglycan-like structure and wide range of outstanding
characteristics such as biodegradability and availability. However,
their application is limited by their poor water solubility under
neutral physiological conditions, poor solubility in organic sol-
vents, and lack of amphipathicity. Moreover, it is known that an in-
crease in the hydrophobicity of a drug-loaded hydrogel, when
administered via the mucosal route, will not only improve drug
encapsulation efﬁciency but also drug transport across the buccal
mucosa [4,5]. Therefore, several chitosan derivatives have been
developed over the years with improved properties for enhanced
applicability [6–8].
Recently, our group developed a novel chitosan derivative (car-
boxymethyl–hexanoyl chitosan, CHC) with excellent water solubil-
ity under neutral conditions [9]. In addition, we found that the
presence of both carboxymethyl (hydrophilic) and hexanoyl
(hydrophobic) groups affords an amphiphilic nature, which might
make CHC suitable for use as a drug-loaded implant material for
poorly water-soluble agents. In an earlier report, it was suggested
that a CHC monolithic drug-loaded membrane could efﬁciently
encapsulate ibuprofen (a nonsteroidal anti-inﬂammatory drug,
IBU) which is poorly water soluble in the neutral physiological
environment. In addition, recently, CHC micelles were also suc-
cessfully prepared and employed for encapsulation of an antitumor
agent with poor water solubility [10]. Moreover, it is expected that
the CHC hydrogel might exhibit pH-sensitive behavior since it
bears both acidic (COOH) and basic (NH2) functional groups. The
effects of the ionic functional groups on the nature of the pH
response of chitosan derivatives have been described by several
researchers [6,11]. However, little research has been done on the
inﬂuence of hydrophobic substitution groups on this pH response.
In our previous study, we performed preliminary investigations on
the water absorption and water retention behavior of CHC [9].
However, it remains unclear whether the ligand substitutions
inﬂuence the pH sensitivity of the resulting amphipathic hydrogel.
In general, the swelling (water absorption) behavior of pH-sen-
sitive hydrogels is determined by the ionization of the functional
groups of hydrogel and the intermolecular volume for water; the
latter depends on the macromolecular structure, the state of water,
the hydrophobic/hydrophilic characteristics, and the electric
charge [12–14]. It is known that these factors also may govern cell
adhesion to materials as well as drug release [15–17]. Hence, the
inﬂuence of the hydrophobic substitution groups on the cell
adhesion and drug release behaviors of the CHC hydrogel were also
investigated in this study. The CHC hydrogel has a hyaluronan-like
structure (Scheme 1) with controlled hydrophilicity/hydrophobic-
ity and therefore has the potential to be employed as an
1742-7061/$ - see front matter  2009 Acta Materialia Inc. Published by Elsevier Ltd. All rights reserved.
doi:10.1016/j.actbio.2009.10.010
* Corresponding author. Tel.: +886 2 28267923; fax: +886 2 28210847.
E-mail address: andyliudpum@yahoo.com.tw (T.-Y. Liu).
Acta Biomaterialia 6 (2010) 1423–1429
Contents lists available at ScienceDirect
Acta Biomaterialia
journal homepage: www.elsevier .com/locate /actabiomat
performed by immersing each sample into solutions of various pH
(pH 1–10) at 20 C for 48 h. The swelling ratio (WS) at equilibrium
was determined by Eq. (1):
WS ¼ ðWwet WdryÞ=Wdry ð1Þ
whereWwet andWdry are the weights of the sample after and before
the swelling test.
2.5. Cytotoxicity and cell adhesion tests
Cytotoxicity tests were performed by the elution method
according to ISO 10993-5. Fibroblast cells (L929) were cultured
in Dulbecco’s modiﬁed Eagle’s medium (DMEM) containing 10% fe-
tal bovine serum and were plated at a density of 2  105 cells ml1
in a 24-well plate at 37 C in 5% CO2 atmosphere. After 24 h of cul-
ture, the medium was replaced with extract ﬂuids obtained by
placing the CHC hydrogel (0.2 g ml1 of culture medium) in the cell
culture medium at 37 C for 24 h. The cells grown in the culture
medium and in that containing 5% dimethylsulphoxide (DMSO)
under the same conditions for 24 h acted as negative and positive
controls, respectively. The adherent cells were trypsinized, centri-
fuged, and resuspended for vital cell counting using a hemacytom-
eter combined with an inverted phase-contrast microscope. For the
cell adhesion test, ﬁbroblast cultures were prepared from the
meninges covering the brains of Wistar rats that were purchased
from the Animal Center, National Taiwan University (Taipei, Tai-
wan). All animals used in the present study were anesthetized
and sacriﬁced in strict adherence to guidelines from the Guide
for the Care and Use of Laboratory Animals (National Institutes of
Health Publication No. 85-23, revised 1985) under a protocol ap-
proved by the Animal Center Committee of National Defense Med-
ical Center. Cells were seeded at 5  105 cells ml1 onto six-well
plates coated with the CHC hydrogel. Cells cultured on chitosan-
coated plates under the same conditions acted as controls. After
24 h of culture, the adherent cells were observed using an inverted
phase-contrast microscope.
2.6. Drug encapsulation efﬁciency and release test
IBUwas employedas apartiallyhydrophobicmodel drug (molec-
ular structure shown in Scheme 2b). IBU-loaded monolithic ﬁlms
(matrix ﬁlms) were prepared from the chitosan derivatives using
the ﬁlm-casting method. In brief, a chitosan/acetic acid solution,
NOCC/DI water solutions, and CHC/ethanol/DI water solutions were
taken and their pH values were adjusted to 7.0 using a 1 M NaOH
solution. These polymeric solutions were then mixed with IBU to
form IBU-loaded polymeric solutions (IBU concentration =
1.2 mg ml1). Subsequently, the drug-loaded polymeric solutions
were poured into Petri dishes and cross-linkedwith genipin to form
drug-loaded matrix ﬁlms after drying at 50 C for 2 days. To calcu-
late the real encapsulation efﬁciency, the cross-linked matrix ﬁlms
were rinsed with an ethanol solution for 30 s and the amount of
IBU rinsed out into the ethanol solution (L2) was determined by
UV–visible spectroscopy (Agilent 8453) at 264.4 nm using a prede-
termined standard concentration–intensity curve. The IBU encapsu-
lation efﬁciency (E) was determined by Eq. (2):
E ¼ ðL1  L2Þ=L1  100% ð2Þ
where L1 is the initial loading amount of IBU incorporated. The IBU
release test was performed by placing the above-mentioned IBU-
loaded membrane (50 mg) in a quartz cuvette containing a release
medium (50 ml) with constant rotary shaking at 37 C. The release
medium (phosphate-buffered solution; pH 7.4) was withdrawn at
speciﬁc time intervals and replaced with an equivalent volume of
fresh buffer. The drug release proﬁle was obtained by plotting a
curve of Mt/M against t, where Mt is the amount of drug released
at time t andM is the amount of drug released once the equilibrium
state is reached.
3. Results and discussion
3.1. Synthesis of CHC
CHC was synthesized from NOCC. Upon ligand substitution, a
hydrogen atom of the amino group was replaced by a hexanoyl
group. The molecular structure is shown in Scheme 1 and the
degree of substitution conﬁrmed by 1H NMR spectra is shown in
Table 1.
3.2. pH-sensitive swelling behavior
The inﬂuence of the carboxymethyl group on the pH sensitivity
is shown in Fig. 1. Both NOCC-1 and NOCC-2 showed similar pH
sensitivity with a transition (i.e. the point with the minimum
swelling ratio) in the range pH 7–8; this is thought to be due to
electrostatic attraction between the COO and NH3
þ groups. Below
and above the transition point, the swelling ratio increased due to
the electrostatic repulsion between the identical NH3
þ groups
ðNH3þ . . .NH3þÞ and the COO groups (COO. . .COO), respectively.
The inﬂuence of the hexanoyl group on the swelling ratio at vari-
ous pH was also investigated. For the CHC and NOCC samples with
the identical degree of carboxymethyl substitution, such as CHC-
1A and NOCC-1, since the number of D-glucosamine residues avail-
able for cross-link of the CHC samples were reduced by hexanoyl
substitution, it is reasonable to believe that the cross-linking de-
gree of CHC-1A was supposed to be higher than that of NOCC-1
while the cross-linking density was ﬁxed. Interestingly, as shown
in Fig. 1, the swelling ratios of CHC-1A and CHC-2A were higher
than those of NOCC-1 and NOCC-2, respectively. This implies that
the roles of carboxymethyl and hexanoyl substitutions on the
swelling behaviors of the chitosan derivatives employed in the
present work need to be further explored. In general, besides the
consideration of cross-linking degree and cross-linking density,
the swelling behavior is determined by intermolecular interactions
such as hydrogen bonding, hydrophobic interaction, and electro-
static interaction, which depend on the macromolecular structure
and the state of water. Therefore, the inﬂuence of hexanoyl substi-
tution on the macromolecular structure and the state of water in
the chitosan derivatives were characterized by ATR–FTIR and DSC.
Fig. 1. Inﬂuence of carboxymethyl and hexanoyl substitution on the swelling ratio
at various pH.
T.-Y. Liu, Y.-L. Lin / Acta Biomaterialia 6 (2010) 1423–1429 1425
considered to be the factors that signiﬁcantly affect cell adhesion
[16,23]. Fig. 6 shows the cell morphology on pristine chitosan-
immobilized plates (a), CHC-2A-immobilized plates (b), and CHC-
2B-immobilized plates (c) after cell seeding for 24 h. We found that
the cells spread extensively on the chitosan-modiﬁed plates and
had a spindle morphology; this contrasted with the cells on the
CHC-2A-immobilized plates, which retained a round morphology.
This difference can be attributed to the fact that the highly swollen
surface of CHC-2A, which has a dynamic hydration layer, retarded
the formation of cell anchorage. Moreover, the electrostatic attrac-
tion between the positively charged chitosan ðNH3þÞ and the neg-
atively charged cell membrane was decreased because of the
degree of hexanoyl substitution. However, as the degree of hexa-
noyl substitution increased further (CHC-2B), the number of adher-
ent cells increased slightly, probably because the hydrophobic
interaction between the hexanoyl groups and cell membrane
favored the formation of initial cell contact [16].
3.4. Drug encapsulation efﬁciency and release behavior
Generally, postoperative tissue adhesion and peritonitis – both
complications of abdominal surgery – can be treated with IBU and
chloramphenicol (a broad spectrum antibiotic), respectively
[24,25]. These two pharmaceutical agents are poorly water soluble
and are therefore dissolved in water-miscible organic solvents and
then encapsulated in amphiphilic matrices [5,26]. IBU is used as an
antiadhesion agent after abdominal surgery because it reduces the
inﬂammatory response and subsequent formation of ﬁbrous tissue
during adhesion; this results in an overall reduction in tissue adhe-
sion after surgery [24,27]. The inﬂuence of degree of both carboxy-
methyl and hexanoyl substitution on the IBU encapsulation
efﬁciency of the NOCC and CHC hydrogels was investigated in
our previous work and it was found that the IBU encapsulation efﬁ-
ciency was signiﬁcantly increased when some of the amino groups
in NOCC were substituted with hexanoyl groups. It is believed that
this occurred because of the increased hydrophobicity of the poly-
mer and the decreased strength of polymer–polymer interactions
[9]. In addition, an interesting phenomenon was further explored
in the present report, as shown in Fig. 7. For the samples without
hexanoyl groups (NOCC-1 and NOCC-2), the degree of carboxy-
methyl substitution did not affect the drug encapsulation efﬁ-
ciency to any great extent. However, for the samples bearing
hexanoyl groups, the degree of carboxymethyl substitution did
signiﬁcantly affect the drug encapsulation efﬁciency. This can be
explained on the basis of the fact that the presence of hexanoyl
groups probably reduces the strength of polymer–polymer interac-
tions, which is favorable to the formation of hydrogen bonds
between the drug molecules (in terms of the ACOOH moiety)
and the unionized groups on the polymer chains, i.e. the COOH
and NH2 groups. Hence, the effect of the degree of carboxymethyl
substitution on the number of drug–polymer binding sites was
pronounced for the samples with hexanoyl groups. Accordingly,
the drug encapsulation efﬁciencies of CHC-1A and CHC-1B (low de-
gree of COOH substitution) were lower than those of CHC-2A and
CHC-2B (high degree of COOH substitution), respectively. This sug-
gests that the carboxymethyl groups play an important role and af-
fect IBU encapsulation efﬁciency if hexanoyl groups are present. In
other words, the effects of carboxymethyl and hexanoyl groups on
the drug–polymer bonding sites are not independent.
Fig. 8 illustrates the IBU release proﬁles from CHC ﬁlms. CHC
samples with a carboxymethyl substitution degree of 0.3
Fig. 5. Cytotoxicity of CHC samples with a carboxymethyl substitution degree of
0.5.
Fig. 6. Cell morphology on chitosan-immobilized plates (a), CHC-2A-immobilized
plates (b), and CHC-2B-immobilized plates (c) after cell seeding for 24 h.
T.-Y. Liu, Y.-L. Lin / Acta Biomaterialia 6 (2010) 1423–1429 1427
Appendix: Figures with essential colour discrimination
Certain ﬁgure in this article, particularly Figure 6, is difﬁcult to
interpret in black and white. The full colour images can be found in
the on-line version, at doi: 10.1016/j.actbio.2009.10.010.
References
[1] Hsu SH, Whu SW, Hsieh SC, Tsai CL, Chen DC, Tan TS. Evaluation of chitosan-
alginate-hyaluronate complexes modiﬁed by an RGD-containing protein as
tissue-engineering scaffolds for cartilage regeneration. Artif Organs
2004;28:693–703.
[2] Yuan Q, Venkatasubramanian R, Hein S, Misra RDK. A stimulus-responsive
magnetic nanoparticle drug carrier: magnetite encapsulated by chitosan-
grafted-copolymer. Acta Biomater 2008;4:1024–37.
[3] Liu H, Li H, Cheng WJ, Yang Y, Zhu MY, Zhou CR. Novel injectable calcium
phosphate/chitosan composites for bone substitute materials. Acta Biomater
2006;2:557–65.
[4] Martin L, Wilson CG, Koosha F, Tetley L, Gray AI, Senel S, et al. The release of
model macromolecules may be controlled by the hydrophobicity of palmitoyl
glycol chitosan hydrogels. J Control Release 2002;80:87–100.
[5] Martin L, Wilson CG, Koosha F, Uchegbu IF. Sustained buccal delivery of the
hydrophobic drug denbufylline using physically cross-linked palmitoyl glycol
chitosan hydrogels. Eur J Pharm Biopharm 2003;55:35–45.
[6] Chen LY, Tian ZG, Du YM. Synthesis and pH sensitivity of carboxymethyl
chitosan-based polyampholyte hydrogels for protein carrier matrices.
Biomaterials 2004;25:3725–32.
[7] Lin YH, Liang HF, Chung CK, Chen MC, Sung HW. Physically crosslinked
alginate/N,O-carboxymethyl chitosan hydrogels with calcium for oral delivery
of protein drugs. Biomaterials 2005;26:2105–13.
[8] Sashiwa H, Kawasaki N, Nakayama A, Muraki E, Yamamoto N, Aiba S. Chemical
modiﬁcation of chitosan. 14: Synthesis of water-soluble chitosan derivatives
by simple acetylation. Biomacromolecules 2002;3:1126–8.
[9] Liu TY, Chen SY, Lin YL, Liu DM. Synthesis and characterization of amphiphatic
carboxymethyl–hexanoyl chitosan hydrogel: water-retention ability and drug
encapsulation. Langmuir 2006;22:9740–5.
[10] Liu KH, Chen SY, Liu DM, Liu TY. Self-assembled hollow nanocapsule from
amphipathic carboxymethyl–hexanoyl chitosan as drug carrier. Macro-
molecules 2008;41:6511–6.
[11] Mi FL, Liang HF, Wu YC, Lin YS, Yang TF, Sung HW, et al. O-carboxymethyl
chitosan and alginate. J Biomater Sci Polym Ed 2005;16:1333–45.
[12] Guan YL, Shao L, Yao KD. A study on correlation between water state and
swelling kinetics of chitosan-based hydrogels. J Appl Polym Sci 1996;61:
2325–35.
[13] Kurkuri MD, Aminabhavi TM. Poly(vinyl alcohol) and poly(acrylic acid)
sequential interpenetrating network pH-sensitive microspheres for the
delivery of diclofenac sodium to the intestine. J Control Release
2004;96:9–20.
[14] Vashuk EV, Vorobieva EV, Basalyga II, Krutko NP. Water-absorbing
properties of hydrogels based on polymeric complexes. Mater Res Innov
2001;4:350–2.
[15] Freier T, Koh HS, Kazazian K, Shoichet MS. Controlling cell adhesion and
degradation of chitosan ﬁlms by N-acetylation. Biomaterials 2005;26:5872–8.
[16] Zhu AP, Fang N. Adhesion dynamics, morphology, and organization of 3T3
ﬁbroblast on chitosan and its derivative: the effect of O-carboxymethylation.
Biomacromolecules 2005;6:2607–14.
[17] Le Tien C, Lacroix M, Ispas-Szabo P, Mateescu MA. N-acylated chitosan:
hydrophobic matrices for controlled drug release. J Control Release
2003;93:1–13.
[18] Muzzarelli RAA. Genipin-crosslinked chitosan hydrogels as biomedical and
pharmaceutical aids. Carbohydr Polym 2009;77:1–9.
[19] Qu X, Wirsen A, Albertsson AC. Novel pH-sensitive chitosan hydrogels:
swelling behavior and states of water. Polymer 2000;41:4589–98.
[20] Goycoolea FM, Heras A, Aranaz I, Galed G, Fernandez-Valle ME, Arguelles-
Monal W. Effect of chemical crosslinking on the swelling and shrinking
properties of thermal and pH-responsive chitosan hydrogels. Macromol Biosci
2003;3:612–9.
[21] Burns JM, Skinner K, Colt J, Sheidlin A, Bronson R, Yaacobi Y, et al. Prevention of
tissue injury and postsurgical adhesions by precoating tissues with hyaluronic
acid solutions. J Surg Res 1995;59:644–52.
[22] Zhou J, Liwski RS, Elson C, Lee TDG. Reduction in postsurgical adhesion
formation after cardiac surgery in a rabbit model using N,O-
carboxymethyl chitosan to block cell adherence. J Thorac Cardiovasc
Surg 2008;135:777–83.
[23] Fang N, Zhu AP, Chan-Park MB, Chan V. Adhesion contact dynamics of
ﬁbroblasts on biomacromolecular surfaces. Macromol Biosci 2005;5:1022–31.
[24] Lee JH, Go AK, Oh SH, Lee KE, Yuk SH. Tissue anti-adhesion potential of
ibuprofen-loaded PLLA-PEG diblock copolymer ﬁlms. Biomaterials
2005;26:671–8.
[25] Nomikos IN, Katsouyanni K, Papaioannou AN. Washing with or without
chloramphenicol in the treatment of peritonitis – a prospective, clinical-trial.
Surgery 1986;99:20–5.
[26] Ridell A, Evertsson H, Nilsson S, Sundelof LO. Amphiphilic association of
ibuprofen and two nonionic cellulose derivatives in aqueous solution. J Pharm
Sci 1999;88:1175–81.
[27] Oh SH, Kim JK, Song KS, Noh SM, Ghil SH, Yuk SH, et al. Prevention of
postsurgical tissue adhesion by anti-inﬂammatory drug-loaded pluronic
mixtures with sol–gel transition behavior. J Biomed Mater Res A
2005;72A:306–16.
T.-Y. Liu, Y.-L. Lin / Acta Biomaterialia 6 (2010) 1423–1429 1429
此次研討會有聽取的 Scientific sessions 與 Mini symposia 分別如下: 
7/12 
Mini-symposium: 
Theranostics: Diagnosis and Treatment in One Box 
Podium Sessions:  
Nanoparticles and Fibers for Controlled Release Systems 
Peptides and Proteins  
Polymers in Medicine 
Pulmonary Delivery  
Translational Studies  
 
7/13 
Podium Sessions: 
Encapsulation for Environmental Protection  
Medical Devices 
Oral Delivery I 
PEGylated Technologies 
Vaccines 
Podium Sessions: 
DNA Delivery 
Encapsulation of Cells and Microorganisms 
Intracellular Trafficking 
Liposomes 
Oral Delivery II 
Tumor Targeting 
 
二. 整體心得： 
在此再次感謝國科會的補助，使個人能參加這次「藥物制放, CRS」領域的國際性研討會
議，這是本人從事教職以來第一次參加 CRS 領域的國際性研討會，此會議是國際間最重要的
藥物制放研討會，其所包含的領域高度聚焦在藥物控制釋放領域，比個人過去曾參加的「生
醫材料」的研討會有更深入的探討，但即使如此，其所牽涉的領域仍相當眾多，因此，許多
演講都是同時進行，必須事先費心挑選主題以免錯失精彩的報告。此經驗是相當珍貴的，希
望藉此次的參與，能多吸取國際上其他學者的優點及經驗，以便對日後的研究會有所幫助。 
本次 CRS 的邀請演講的內容趨勢，與筆者在學生時待所參加的 2004 CRS 已經有所差別， 
前次比較多 DDS 在組織工程與傷口復原的應用，此次會議似乎比較多奈米技術的創新發展，
例如有講者提到非常具有創新性的奈米結構，一種金的立方中空結構，非常新奇；也有比較
多的 DDS 運用在基因治療的報導；同時，也開始有轉譯醫學的演講；最重要的，結合診斷與
治療的新概念已確定成形，這個部分與本人現在的研究比較有關連，因此，如何結合造影與
藥物控制釋放應是未來 3 年的重要研究趨勢。 
這次國際會議，是由 Controlled release society 主辦，與會人士主要來自美國，部份來自
其他國家，亞洲國家中看來以日、韓與中國大陸為主，此次研討會比較少看到台灣的學者或
學生，反倒是看到許多來自中國的學生或是中國留美的留學生。整體而言，報告者的研究水
平相當高；於美國舉行的研討會，常看到聽講者提出尖銳的問題，這個現象在本研討會也相
 
 
附件一. 海報論文發表 
 
 
附件二. 投影片筆記選輯: 奈米科技、基因治療與分子影像 
 
 
 
 
 
 
 
97年度專題研究計畫研究成果彙整表 
計畫主持人：劉澤英 計畫編號：97-2221-E-010-012-MY2 
計畫名稱：具有水難溶藥物包覆能力的超音波敏感釋控材料開發及其奈米結構設計(II) 
量化 
成果項目 實際已達成
數（被接受
或已發表）
預期總達成
數(含實際已
達成數) 
本計畫實
際貢獻百
分比 
單位 
備 註 （ 質 化 說
明：如數個計畫
共同成果、成果
列 為 該 期 刊 之
封 面 故 事 ...
等） 
期刊論文 0 0 100%  
研究報告/技術報告 0 0 100%  
研討會論文 3 3 100% 
篇 
 
論文著作 
專書 0 0 100%   
申請中件數 0 0 30%  專利 已獲得件數 0 0 100% 件  
件數 0 0 100% 件  
技術移轉 
權利金 0 0 100% 千元  
碩士生 6 6 100%  
博士生 0 0 100%  
博士後研究員 0 0 100%  
國內 
參與計畫人力 
（本國籍） 
專任助理 0 0 100% 
人次 
 
期刊論文 2 2 75%  
研究報告/技術報告 0 0 100%  
研討會論文 2 0 100% 
篇 
 
論文著作 
專書 0 0 100% 章/本  
申請中件數 0 0 30%  專利 已獲得件數 0 0 100% 件  
件數 0 0 100% 件  
技術移轉 
權利金 0 0 100% 千元  
碩士生 0 0 100%  
博士生 0 0 100%  
博士後研究員 0 0 100%  
國外 
參與計畫人力 
（外國籍） 
專任助理 0 0 100% 
人次 
 
 
